Allos is a solution to prognose, monitor, and treat autoimmune conditions.
Allos has raised $5.0M in total funding. The most recent round was Seed. The last funding was announced in January 2026.
Allos's investors include Oxford Science Enterprises, SkyDeck Berkeley, TMU BioMed Accelerator, Habico Invest.
Allos is headquartered in London, United Kingdom.
Allos is a solution to prognose, monitor, and treat autoimmune conditions.
Allos is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Allos — Funding & Investors." VCBacked, January 12, 2026, https://www.vcbacked.co/company/allos. Accessed October 30, 2026.
VCBacked. (2026). Allos — Funding & Investors. Retrieved October 30, 2026, from https://www.vcbacked.co/company/allos
{{cite web |title=Allos — Funding & Investors |url=https://www.vcbacked.co/company/allos |website=VCBacked |access-date=October 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated